Currently Viewing:
Newsroom
Currently Reading
Mechanism for Checkpoint Inhibitor Resistance Identified in Invasive Bladder Cancer
July 25, 2017 – Christina Mattina
What We're Reading: Monthly HIV Shot; Molina Layoffs; Charlie Gard Treatment
July 25, 2017 – AJMC Staff
Barriers to Recruiting ED Patients With Advanced Cancer for Palliative Care
July 25, 2017 – Surabhi Dangi-Garimella, PhD
Immune-Cell Numbers Determine Combination Immunotherapy Response in Melanoma Patients
July 25, 2017 – Alison Rodriguez
Study of 1.7 Million Patients Finds Strong Link Between Teenage Obesity, Colon Cancer Risk
July 24, 2017 – Mary Caffrey
Kite's CAR-T Therapy Produces Durable Remission in DLBCL, Study Finds
July 24, 2017 – Christina Mattina
This Week in Managed Care: July 21, 2017
July 21, 2017
Social Interaction Among Patients During Chemotherapy Affects Treatment Response
July 21, 2017 – Alison Rodriguez
Study Queries Cost—Quality Tradeoff in Narrow Oncology Provider Networks
July 20, 2017 – Surabhi Dangi-Garimella, PhD

Mechanism for Checkpoint Inhibitor Resistance Identified in Invasive Bladder Cancer

Christina Mattina
Researchers have identified a cellular signaling pathway that when activated by mutations may prevent immune cells from infiltrating bladder tumors, thus making the cancer resistant to immune checkpoint inhibitors.
Researchers have identified a cellular signaling pathway that when activated by mutations may prevent immune cells from infiltrating bladder tumors, thus making the cancer resistant to immune checkpoint inhibitors.

According to the study, published in Nature Communications, immunotherapies such as the checkpoint inhibitor anti-programmed death-ligand 1 (PD-L1) have shown promising results in treating aggressive tumors like muscle-invasive bladder cancer. However, they are not reliably effective, as the majority of patients show no response to the treatment, leading researchers to investigate the specific genomic mutations and cell pathways that may contribute to immunotherapy resistance.

The study authors analyzed cancer genome alterations gathered from genomic databases, including The Cancer Genome Atlas, and identified several genetic alterations prominently expressed in bladder cancer patients. After modeling the transcriptional impact of each of these mutations, they determined that overexpression of some locations on retinoid X receptor alpha (RXRαS427F/Y) and/or peroxisome proliferator-activate receptor gamma (PPARγ) can activate the PPARγ pathway. This pathway, they found, suppresses the secretion of cytokines from cancer cells, creating an immunosuppressive environment that inhibits the chemokines that have been linked to better response to anti-PD-L1 treatment in patients with bladder cancer . Essentially, this pathway determines whether the body’s immune cells, activated by the checkpoint inhibitors, can invade the bladder tumor.

“Collectively, our findings suggest that the PPARγ/RXRαS427F/Y pathway in tumor cells might influence the activity/localization of host immune cells and potentially blunt response to immunotherapy,” the study summarized.

The finding could have important implications for reversing immunotherapy resistance. Further analyses described in the study suggest that targeting the pathway in question “may serve as a viable therapeutic node for activating immunosurveillance,” which could boost patients’ response to immune checkpoint inhibitors.

According to a media statement from the University of British Columbia (UBC), knowing that the pathway allows the tumor to “close the door to the immune system” will enable scientists to concentrate their “efforts on breaking down that door and let the immune system back in,” in the words of co-author Mads Daugaard, PhD, assistant professor at UBC and senior research scientist at the Vancouver Prostate Centre.

“Further understanding of the regulatory mechanisms and deeper identification of relevant pathways/targets in specific tumors should pave the way for the next-generation cancer immunotherapies,” the researchers wrote in the article.

In the meantime, Daugaard and his colleagues are working to create a drug to be given in combination with checkpoint inhibitors that would target the PPARγ pathway.

“The most efficient way to combat a cancer would be to have the immune system take care of it itself,” said Daugaard in the press release. “This is ultimately what we want to achieve.”

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up